Today’s Free Research Reports Coverage on Agenus and Three More Biotech Stocks

Stock Research Monitor: AFMD, AKCA, and AKBA

LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on AGEN sign up now at www.wallstequities.com/registration. Focus is shifted on Biotechnology, which has been instrumental in the initial drug discovery and screening stages. Most major pharmaceutical companies have active target-discovery research programs heavily reliant on biotechnology, and smaller new companies do focused drug discovery and development often using unique proprietary techniques. In today’s pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (NASDAQ: AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA).

All you have to do is sign up today for this free limited time offer by clicking the link below:

www.wallstequities.com/registration

Affimed

Last Friday, Heidelberg, Germany headquartered Affimed N.V.’s stock closed the day flat at $2.15. A total volume of 457,635 shares was traded, which was above their three months average volume of 363,310 shares. The Company’s shares are trading 8.38% above their 200-day moving average. Additionally, shares of Affimed, which focuses on discovering and developing cancer immunotherapies in Germany and internationally, have a Relative Strength Index (RSI) of 44.99.

On May 18th, 2018, Affimed announced that its Annual General Meeting of Shareholders will be held on June 19th, 2018, starting at 3:00 p.m. CET. The meeting will be held at Amsterdam Marriott Hotel, Stadhouderskade 12, 1054 ES Amsterdam, the Netherlands. The notice and agenda of the general meeting will available, free of charge, in the Investor Relations section of the Company’s corporate website, under “Notice to convene the Annual General Meeting of Shareholders of Affimed N.V.” Get the full research report on AFMD for free by clicking below at:

www.wallstequities.com/registration/?symbol=AFMD

Agenus

Shares in Lexington, Massachusetts headquartered Agenus Inc. finished Friday’s session flat at $3.10. The stock recorded a trading volume of 1.16 million shares. The Company’s shares are trading below their 50-day moving average by 17.31%. Furthermore, shares of Agenus, which focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer, have an RSI of 28.99.

On June 04th, 2018, Agenus presented updated clinical data on its lead CTLA-4 and PD-1 programs at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago. The Company is expanding beyond these backbone I-O compounds with six planned INDs in 2018 and two additional INDs in 1H2019. Free research on AGEN can be accessed at:

www.wallstequities.com/registration/?symbol=AGEN

Akcea Therapeutics

Cambridge, Massachusetts headquartered Akcea Therapeutics Inc.’s stock finished 0.86% lower at $21.87 last Friday at the close. A total volume of 180,980 shares was traded. The Company’s shares have advanced 16.33% in the past month and 13.14% in the previous three months. The stock is trading above its 200-day moving average by 1.18%. Additionally, shares of Akcea Therapeutics, which focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the US and internationally, have an RSI of 43.83.

On May 11th, 2018, research firm Wells Fargo upgraded the Company’s stock rating from ‘Market Perform’ to ‘Outperform’.

On June 05th, 2018, Akcea Therapeutics announced the appointment of Richard “Rich” A. Moscicki, M.D., to the Company’s Board of Directors. Dr. Moscicki has been the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America since he joined in 2017. Visit WallStEquities.com now and sign up for the free research on AKCA at:

www.wallstequities.com/registration/?symbol=AKCA

Akebia Therapeutics

Cambridge, Massachusetts headquartered Akebia Therapeutics Inc.’s shares ended the session 2.97% higher at $10.39. The stock recorded a trading volume of 343,513 shares. Shares of the Company have advanced 9.25% in the last month. The stock is trading 6.05% above its 50-day moving average. Moreover, shares of Akebia Therapeutics, which focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor biology, have an RSI of 57.27.

On June 04th, 2018, Akebia Therapeutics (AKBA) announced that it granted four, newly hired employees options to purchase an aggregate of 21,300 shares of AKBA common stock on May 31st, 2018, as inducements material to each employee’s entering into employment with the Company. The options have an exercise price of $9.82 per share, which is equal to the closing price of the Company’s common stock on the grant date.

On June 06th, 2018, research firm H.C. Wainwright reiterated its ‘Buy’ rating on the Company’s stock with a decrease of the target price from $24 a share to $22 a share. The free technical report on AKBA is available at:

www.wallstequities.com/registration/?symbol=AKBA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 502273